Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039105 | 1.00 | L3MBTL1 (0.47) | L3MBTL1PKMCTSBCTSSCTSK | |
| SCHEMBL4819619 | 0.84 | L3MBTL1 (0.47) | L3MBTL1PKMCTSBCTSSCTSK | |
| SCHEMBL24098175 | 0.82 | L3MBTL1 (0.48) | L3MBTL1PKMCTSBCTSSCTSK | |
| SCHEMBL19849366 | 0.82 | L3MBTL1 (0.48) | L3MBTL1PKMCTSBCTSSCTSK | |
| SCHEMBL20879973 | 0.82 | L3MBTL1 (0.48) | L3MBTL1PKMCTSBCTSSCTSK | |
| SCHEMBL4824959 | 0.80 | TAAR1 (0.40) | TAAR1GRM4ALDH1A1POLBCACNA1G | |
| SCHEMBL4598377 | 0.80 | TAAR1 (0.40) | TAAR1GRM4ALDH1A1POLBCACNA1G | |
| SCHEMBL4598385 | 0.80 | TAAR1 (0.40) | TAAR1GRM4ALDH1A1POLBCACNA1G | |
| SCHEMBL24334219 | 0.79 | L3MBTL1 (0.46) | L3MBTL1PKMCTSBCTSSCTSK | |
| SCHEMBL11616910 | 0.79 | NAAA (0.53) | L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | claimed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | L3MBTL1 2741/4885PKM 2477/4885CTSB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.